|
|
Volumn 289, Issue 24, 2003, Pages 3227-3229
|
|
Accelerated Approval Scrutinized: Confirmatory Phase 4 Studies on New Drugs Languish
a
a
NONE
|
|
Author keywords
[No Author keywords available]
|
|
Indexed keywords
DENILEUKIN DIFTITOX;
DOCETAXEL;
GEFITINIB;
NEW DRUG;
PLATINUM DERIVATIVE;
ANTINEOPLASTIC AGENT;
QUINAZOLINE DERIVATIVE;
CLINICAL TRIAL;
DRUG APPROVAL;
DRUG EFFICACY;
DRUG LEGISLATION;
DRUG MARKETING;
DRUG RESPONSE;
DRUG SAFETY;
FOOD AND DRUG ADMINISTRATION;
HUMAN;
LUNG INJURY;
LUNG NON SMALL CELL CANCER;
PHASE 4 CLINICAL TRIAL;
POSTMARKETING SURVEILLANCE;
PRIORITY JOURNAL;
REVIEW;
RISK BENEFIT ANALYSIS;
ARTICLE;
UNITED STATES;
ANTINEOPLASTIC AGENTS;
CLINICAL TRIALS, PHASE IV;
DRUG APPROVAL;
QUINAZOLINES;
UNITED STATES;
UNITED STATES FOOD AND DRUG ADMINISTRATION;
|
|
EID: 0038167824
PISSN: 00987484
EISSN: None
Source Type: Journal
DOI: 10.1001/jama.289.24.3227 Document Type: Review |
|
Times cited : (14)
|
|
References (0)
|